

C² 37. (Amended) The vaccine composition directed against malaria according to claim 36, wherein said T epitope is selected from the group of: an amino acid sequence of ^{41 only} SEQ ID NOS:39-42, an amino acid sequence of SEQ ID NOS:43-46 and an amino acid sequence of SEQ ID NO:19.

REMARKS

Entry of the foregoing and prompt and favorable consideration of the subject application, in light of the following remarks, are respectfully requested.

By the present Third Supplemental Preliminary Amendment, claims 32 and 37 have been amended to recite the appropriate sequence identifiers as required by the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures. No new matter has been added.

In the event that there are any questions relating to this application, it would be appreciated if the Examiner would telephone the undersigned attorney concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Nicole E. Kinsey
Nicole E. Kinsey, Ph.D.
Registration No. P-50,723

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: February 21, 2002

Attachment to Amendment dated February 21, 2002
Marked-up Claims

32. (Amended) The polypeptide according to claim 31, wherein said T epitope has an amino acid sequence selected from the group of the amino acid [sequence of Figures 9A-9D and the amino acid sequence of Figures 10A-10D] sequences of SEQ ID NOS:39-46.

37. (Amended) The vaccine composition directed against malaria according to claim 36, wherein said T epitope is selected from the group of: an amino acid sequence of [Figures 9A-9D] SEQ ID NOS:39-42, an amino acid sequence of [Figures 10A-10D] SEQ ID NOS:43-46 and an amino acid sequence of SEQ ID NO:19.